EUCTR2015-000520-29-DE进行中（未招募）1 期
Treatment of Advanced Gastrointestinal Adenocarcinoma in a Phase I/II trial with modified allogeneic MSC_apceth_111 - TREAT-ALL 1
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Age = 18 years.
- •2. Patients with advanced or recurrent or metastatic gastrointestinal adenocarcinoma.
- •Target indication:
- •- Gastric cancer (cTNM: T3NxMx or T4NxMx) (including gastro-esophageal junction) or
- •- Pancreatic cancer (cTNM: T3NxMx) or
- •- Metastatic colorectal cancer (cTNM: TxNxM1) or
- •- Cholangiocellular carcinoma (cTNM: T3NxMx or T4NxMx)
- •The TNM classification should not be older than 4 months.
- •3. Premature or scheduled termination of standard therapy (including possible preoperative therapy; for details see CTP section 7) due to intolerability / progress / inefficacy or no acceptance by the patient, if relapses/metastases are measurable by means of imaging techniques.
- •4. No relapse and no single metastasis should exceed 5 cm in its maximal diameter.
- •5. In case of metastases due to colorectal cancer:
- •- Metastases are unresectable
- •- The total volume of the liver metastases does not exceed 30 % of the total liver volume
- •- In addition to liver metastases lung metastases (as assessed by a radiologists with a minimum diameter of at least 0,5 cm) are allowed, however, not more than 10 with the largest one not exceeding 2,0 cm in diameter
- •- Lymph node metastases are permitted
- •- Brain metastases: As long as only one organ is affected by extra-cranial metastases due to colorectal cancer no radiological investigation for brain metastases is needed if there are no signs or symptoms suspicious for brain metastases. In case of liver and lung metastases the patient has to be excluded unless a cranial image verifies absence of brain metastases.
- •6. Progressive disease as clinically assessed by the investigator.
- •7. Adequate organ function:
- •- Hb > 9.0 g/dl
- •- WBC > 3,000 cells/µl and Neutrophils >500 /µl
- •- Platelets > 100,000 cells/µl
- •- ALT/AST = 5 ULN
- •- total bilirubin = 3 ULN
- •- Creatinine = 2.0 mg/dl and creatinine clearance = 50 ml/min
- •8. General condition ECOG 0-1.
- •9. Anticipated minimal life expectancy of at least 3 months.
- •10. Men and women of reproductive potential must agree to follow accepted contraception methods during treatment and for 3 months after completion of treatment. Medically acceptable methods of birth control are methods with a low failure rate of less than 1% per year; e.g. hormonal contraceptives for at least 7 days before trial enrollment or an intrauterine device, or double barrier method (male or female condom or diaphragm, in combination with a spermicidal gel). All women, including those with tubal ligation, are considered to be of childbearing potential unless they have been postmenopausal for at least 2 years. Hysterectomized women are considered surgically sterile and are not required to use any contraception.
- •Males should not participate in a sperm donation program.
- •11. Ability of patient to understand character and individual consequences of clinical trial.
- •12. Written informed consent must be available before any study specific procedure is performed.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 15
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 15
排除标准
- •1. Patients with severe heart diseases: NYHA stage III and IV; unstable angina pectoris, or myocardial infarction during the last 8 weeks before Visit 1 (Baseline).
- •2. Clinical significant ischemic disease during the last 4 weeks before Visit 1 (Baseline).
- •3. Severe lung disease: COPD Grade III, Asthma bronchiale Grade IV, lung fibrosis.
- •4. Clinically relevant ascites / peritoneal carcinomatosis.
- •5. Symptomatic pleural or pericardial effusion.
- •6. Serious uncontrolled acute infections less than 3 weeks before Visit 1 (Baseline).
- •7. Patients with HCV infection as defined by anti-HCV pos and HCV RNA pos and / or HBV infection as defined by anti-Hbc pos and/ or HBV DNA pos.
- •8. Patients with HIV infection as minimally demonstrated by HIV RNA.
- •9. Immunodeficiencies or systemic autoimmune diseases (e.g. M. Crohn, Colitis ulcerosa) or known malformations of the gastrointestinal tract.
- •10. Active infection with HSV (by IgM pos).
- •11. Patient with detection of anti-HLA Abs (pos) at screening prior to MSC_apceth_111 infusion.
- •12. Second carcinoma in addition to the underlying carcinoma unless the second carcinoma was curatively and successfully resected more than 5 years ago before Visit 1 (Baseline) (exception: basal cell carcinoma, precancerous conditions).
- •13. Use of any immunomodulators.
- •14. Need for any standard anti-tumor therapy like chemo-, targeted immuno-, cytokine and radiotherapy in the time interval 2 weeks before infusion of MSC_apceth_111 or anticipation of chemo- or radiotherapy during treatment with MSC_apceth_111 and GCV until 2 days after the last administration of GCV.
- •15. Known dependency on alcohol or other drugs.
- •16. Committed to an institution by way of official or judicial order.
- •17. Patients requiring corticoids in doses above the Cushing threshold.
- •18. Known liver fibrosis or liver cirrhosis.
- •19. Any concomitant severe disease which could compromise the objectives of this study in the judgment of the investigator.
- •20. Pregnant or breast feeding female patient
- •21. Any surgery in the last four weeks before the administration of MSC_apceth_111.
- •22. History of hypersensitivity to the investigational product or to Ganciclovir, Valganciclovir, Aciclovir or Valaciclovir.
- •23. Any contraindication to Ganciclovir (see current SmPC) or the need for the following drugs interacting with Ganciclovir: Probenecid; combination of Imipenem-Cilastatin; Dapson, Pentamidin; Flucystosin; Vincristin, Vinblastin, Adriamycin, Amphotericin B; combination of Trimethoprim and Sulfonamides, Nucleosideanaloga or Hydroxy-urea.This is confined to the time period 14 days prior to Ganciclovir and up to 7 days after termination of Ganciclovir treatment
- •24. Participation in another clinical trial, respectively, during the last 4 weeks prior to the first MSC_apceth_111 dose.
研究者
相似试验
进行中（未招募）
1 期
Treatment of Advanced Gastrointestinal Cancer in a Phase I/II trial with modified autologous MSC_apceth_101EUCTR2012-003741-15-DEapceth GmbH & Co. KG
招募中
不适用
SURGERY FOR ADENOCARCINOMA OF THE GASTROESOPHAGEAL JUNCTION (GEJ) TYPE II: TRANSTHORACIC ESOPHAGECTOMY VS. TRANSHIATAL EXTENDED GASTRECTOMY (CARDIA trial)NL-OMON52610niversity of Cologne, Germany20
进行中（未招募）
不适用
ltrasound-assisted treatment of inoperable pancreatic cancer. ”Behandling av inoperabel kreft i bukspyttkjertelen ved å kombinere kontrast ultralyd og gemcitabin under sonoporering”Patients with inoperable pancreatic cancer.Histologically verified, locally advanced (nonresectable Stage II/III) or metastatic (Stage IV) adenocarcinoma of the pancreas. The patients must be ambulatory with an ECOG performance status 0-2.EUCTR2010-024289-24-NOHelse Bergen HF, Haukeland Unversity Hospital10
招募中
4 期
Surgery for adenocarcinoma of the gastroesophageal junction (GEJ) type II:Transthoracic esophagectomy vs. transhiatal extended gastrectomy.C16.0CardiaDRKS00016923niversitätsklinik Köln Klinik und Poliklinik für Allgemein- Viszeral- und Tumorchirurgie262
进行中（未招募）
1 期
Treatment of pancreatic adenocarcinoma with the combinationof carboplatin and velparibEUCTR2014-003785-24-HUzsoki Utcai Kórház